Revelation Biosciences, Inc. (NASDAQ:REVB) Shares Shorted: Short Interest Up 317.8% in October

Revelation Biosciences, Inc. (NASDAQ:REVB) saw a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 6,605 shares, a growth of 317.8% from the September 30th total of 1,581 shares. Currently, 1.0% of the company’s shares are sold short. Based on an average daily trading volume, of 41,123 shares, the days-to-cover ratio is presently 0.2 days.

Revelation Biosciences Price Performance

Revelation Biosciences stock opened at $3.75 on Friday. The firm has a market capitalization of $2.55 million, a P/E ratio of -0.04 and a beta of -0.07. Revelation Biosciences has a 1-year low of $3.08 and a 1-year high of $40.60. The company’s 50-day moving average is $5.84 and its 200 day moving average is $8.44.

Revelation Biosciences (NASDAQ:REVB) last announced its earnings results on Thursday, August 6th. The company reported ($6.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.12) by $0.03. Research analysts anticipate that Revelation Biosciences will post -36.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research note on Wednesday, October 14th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

About Revelation Biosciences

Revelation Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies that stimulate the body’s innate immune system. The company’s research is centered on immunologic treatments intended to help prevent or manage infectious and other acute diseases.

Its lead development programs are based on Gemini, a proprietary toll-like receptor 4 agonist designed to activate innate immune responses. Revelation has investigated intranasal formulations, including REVTx-99, for potential use against respiratory viral infections, as well as other candidates aimed at addressing serious medical conditions such as sepsis.

Revelation Biosciences is headquartered in San Diego, California, and has focused primarily on advancing its pipeline through preclinical and clinical development rather than marketing approved commercial products.